Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Asset Writedowns and Impairment (2024 - 2025)

Historic Asset Writedowns and Impairment for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to $1.4 million.

  • Iovance Biotherapeutics' Asset Writedowns and Impairment changed N/A to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year change of. This contributed to the annual value of $7.4 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Asset Writedowns and Impairment of $1.4 million as of Q3 2025.
  • Iovance Biotherapeutics' 5-year Asset Writedowns and Impairment high stood at $7.4 million for Q4 2024, and its period low was $1.4 million during Q3 2025.